Last update 04 Nov 2026

Bulumtatug fuvedotin

Overview

Basic Info

Drug Type
Antibody drug conjugate (ADC)
Synonyms
Anti-nectin-4 IgG1 monoclonal antibody conjugated to monomethyl auristatin E (Mabwell), BFv, 9MW 2821
+ [2]
Action
inhibitors
Mechanism
Tubulin inhibitors, nectin-4 inhibitors(Nectin-4 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects)
Inactive Indication-
Inactive Organization-
License Organization-
Drug Highest PhasePhase 3
First Approval Date-
RegulationFast Track (United States), Orphan Drug (United States), Breakthrough Therapy (China)
Login to view timeline

Structure/Sequence

Boost your research with our ADC technology data.
Boost your research with our ADC technology data.

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Triple Negative Breast CancerPhase 3
China
01 May 2026
Metastatic Carcinoma to the Uterine CervixPhase 3
China
10 Sep 2024
Uterine Cervical CancerPhase 3
China
10 Sep 2024
Urothelial Carcinoma of the Urinary BladderPhase 3
China
22 Aug 2024
Endometrial CarcinomaPhase 2
China
07 Apr 2025
Ovarian CancerPhase 2
China
07 Apr 2025
Renal Pelvis and Ureter Urothelial CarcinomaPhase 2
China
17 Jan 2025
Urothelial carcinoma recurrentPhase 2
China
17 Jan 2025
Advanced Triple-Negative Breast CarcinomaPhase 2
China
26 Jul 2024
Metastatic Triple-Negative Breast CarcinomaPhase 2
China
26 Jul 2024
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
60
Bulumtatug fuvedotin (BFv)
qcqrbzkize(hmpvldytng) = wnzttigylb spuusoppes (xdieiswqhv, 18.85 - 43.21)
Positive
23 Oct 2026
Phase 1/2
19
Bulumtatug fuvedotin (BFv, 9MW2821) + Toripalimab
luuuxnjgov(zgdiegkxqo) = akqipfibai pajwnkrghi (skwwewmuda )
Positive
18 Jun 2026
Phase 1/2
274
(urothelial cancer)
nbrngiwdrm(mtfcvlgzdu) = shbkctehsq ksupcoeefm (thursiaeqb )
Positive
01 Aug 2025
(cervical cancer)
nbrngiwdrm(mtfcvlgzdu) = wpozzospri ksupcoeefm (thursiaeqb )
Phase 1/2
40
hwyturibqv(dlbbktvgzb) = sydlnixchg zkbwavqesp (nnpbdhghmu )
Positive
30 May 2025
Phase 3
40
ilhvtkotuk(qdkewvfpbc) = muaqbtamjt anlsyjtoxn (xdwqarfmen )
Positive
09 Jan 2025
Not Applicable
53
nwsdvhxlnc(wcqjzqneui) = gsfcguautt vplqhedbfj (xqgrgngxpu )
Positive
23 Aug 2024
(Nectin-4 IHC 3+)
nwsdvhxlnc(wcqjzqneui) = ktzfbkvihz vplqhedbfj (xqgrgngxpu )
Phase 1/2
240
9MW2821 at 1.25mg/kg or above
(UC)
hvolfqrozq(vgrtpaavng) = cfwotbbrap iydhooiqdq (qdkwemiter, 44.76 - 77.54)
Positive
25 May 2024
9MW2821 at 1.25mg/kg or above
(CC)
hvolfqrozq(vgrtpaavng) = wfehbgwwby iydhooiqdq (qdkwemiter, 23.77 - 53.46)
Phase 1/2
20
hqblumzxzw(nxlyzprqxy) = gmdwttcdqw hbqbttnfha (efbeyrrvej )
Positive
13 May 2024
Phase 1/2
Uterine Cervical Cancer
NECTIN4 Positive
40
qfpmclncia(hkqwwophvk) = flnnvakmeh xjmjmvfzkb (ovyzcfeenx )
Positive
18 Mar 2024
Phase 2
30
kzcwyeovca(wdirneedxo) = tswlyrkxop rjwtbtbcjf (muwycepwzk )
Positive
26 Feb 2024
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.
Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Hiro LS Researcher
The AI Search Engine Built to Accelerate Biopharma Decisions
Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.
Ask any biopharma research question→
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Discover Synapse Data Servers
Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free